DENTALMONITORING
21.10.2021 11:24:09 CEST | Business Wire | Press release
DentalMonitoring has become the first dental software company to attain a valuation over $1 billion announcing a $150 million growth financing. The round is led by a new investment of $90 million from Mérieux Equity Partners and $60 million from Vitruvian Partners, an existing financial investor, demonstrating confidence in the company’s ambitious plans.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005463/en/
Since CEO and co-founder Philippe Salah launched the company in 2014, DentalMonitoring has become the first player to harness AI for remote monitoring in the dental and orthodontic fields. Driven by the treating doctor, DentalMonitoring’s AI automates messages and instructions sent to patients and practice staff to synchronize the delivery of care with the need of care. DentalMonitoring is also the first and only company offering virtual practice solutions for all dental professionals to help streamline and automate their workflow from initial virtual consultation, patient triage and conversion, to remote monitoring of all appliances and brands. To date, there are over one million patients in more than 50 countries that have taken more than a billion intraoral images on the DentalMonitoring platform.
“We are proud to be supported by leading international funds,” says DentalMonitoring CEO Philippe Salah. “This achievement marks a new milestone for the company, and is a testament to the new standard of care our team has brought to the profession. We will continue to deliver even more innovative solutions for dental professionals to help them provide better care and scale their practices.”
The company plans to use the proceeds to finance its rapid global growth, targeting an increased presence in the U.S. and expanding into new markets such as China and Japan. DentalMonitoring also plans to nearly double the number of employees in the next two years and target relevant acquisitions.
“AI is one of the major technologies to transform the delivery of healthcare and improve patient outcomes. DentalMonitoring’s team and their disruptive technology have convinced us of their ability to address the expanding demand for remote care capabilities for dental professionals. We are proud at Mérieux Equity Partner to back healthtech talent and look forward to supporting DentalMonitoring in their stellar growth, leveraging our international network.” added Caroline Folleas of Mérieux Equity Partners.
“By enabling remote dental care, DentalMonitoring is the biggest disruptor to the field since intraoral scanners in the 1990s and digital imaging in the 1980s. The company is an excellent fit with our investment strategy of backing best-in-class companies benefiting from strong market tailwinds with internationalization opportunities. Vitruvian renews its confidence to support the increasing needs of the company’s ambitious growth plans.” says Torsten Winkler of Vitruvian Partners.
Jefferies LLC, a global investment bank with a deep knowledge of the dental and software markets, served as Sole Placement Agent to DentalMonitoring on this investment round.
About DentalMonitoring
-
www.dental-monitoring.com
DentalMonitoring was started with a simple idea: oral care should be connected and continuous — even outside the practice. The company has created the world’s first virtual practice platform in dentistry, protected by over 200 patents, to address rapidly evolving patient expectations. Thanks to the largest database of dental images in the industry, DentalMonitoring has developed the most advanced and comprehensive doctor-driven AI solutions to help dental professionals provide superior care and a better patient experience. From patient lead engagement and conversion, providing treatment options through AI-generated reporting and advanced smile simulations, to remote monitoring of all types of treatments, DentalMonitoring’s unique platforms give dental professionals complete control over streamlined assessments and communication. DentalMonitoring has over 400 employees across 18 countries and 9 offices including Paris, Austin, London, Sydney and Hong Kong.
About Mérieux Equity Partners
- www.merieux-partners.com
Merieux Equity Partners ("MxEP") is an AMF-accredited management company dedicated to equity investments in the health and nutrition sector. With more than 45 companies backed, MxEP actively supports entrepreneurs and companies whose products and services bring differentiated and innovative solutions by providing privileged access to its expertise and the industrial, scientific and commercial network of Institut Mérieux (BioMerieux, Transgene, ABL, Mérieux Nutrisciences); MxEP currently manages over €1 billion in assets.
About Vitruvian Partners
- www.vitruvianpartners.com
Vitruvian is a leading international growth investor headquartered in London with offices in London, Stockholm, Munich, Luxembourg, San Francisco and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries. Vitruvian has backed over 100 companies and has assets under management of approximately €10 billion. Notable investments include global market leaders and disruptors in their field such as CRF Health, Fotona, Ada, doctari, Vestiaire Collective, Farfetch, Just Eat, Marqeta and TransferWise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005463/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom